Update on the management of symptoms in schizophrenia: Focus on amisulpride

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 267-277

  Mortimer, Ann M ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Amisulpride; Clozapine; Depression; Negative symptoms

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUOXETINE; FLUPENTIXOL; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

BINDING AFFINITY; CATAPLEXY; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSTHYMIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MAJOR DEPRESSION; METABOLIC DISORDER; MONOTHERAPY; NEGATIVE SYNDROME; NEUROSCIENCE; NONHUMAN; NOTE; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; POSITIVE SYNDROME; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; SINGLE DRUG DOSE; SOCIAL INTERACTION; TREATMENT DURATION; WEIGHT GAIN;

EID: 70449724705     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s3949     Document Type: Note

References (139)

1. Guo N, Guo W, Guillin O, Laruelle M, Javitch J, Rayport S. The surface D2-binding profile of the atypical antipsychotic drug amisulpride. J Cereb Blood Flow Metabo. 2007;27(suppl 1):PO03-02U. (Pubitemid 350155902)
2. Kerwin R. From pharmacological profiles to clinical outcomes. Int Clini Psychopharmacol. 2000;15(suppl 4):S1-S4.
3. Di Giovanni G, Di Mascio M, Di Matteo V, Esposito E. Effects of acute and repeated administration of amisulpride, a dopamine D2 D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons. J Pharmacol Exp Ther. 1998;287(1):51-57. (Pubitemid 29140185)
4. Perrault G, Depoortere R, Morel E, Sanger D, Scatton B. Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2 D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997;280(1):73-82. (Pubitemid 27171390)
5. Navarro J, Manzaneque J, Vera F, Martin-Lopez M, Santin L. Amisulpride, a presynaptic D2 D3, dopamine receptor antagonist, induces catalepsy in mice. Med Sci Res. 1997;25(8):551-552. (Pubitemid 27389122)
6. Martinot J, Paillere-Martinot M, Poirier M, Dao-Castellana M, Loc'h C, Maziere B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Source Psychopharmacol. 1996;124(1-2):154-158. (Pubitemid 26112784)
7. Xiberas X, Martinot J-L, Mallet L, et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clini Psychopharmacol. 2001;21(2):207-214. (Pubitemid 32221059)
8. Stone J, Bressan R, Erlandsson K, Ell P, Pilowsky L. Non-uniform blockade of intrastriatal D2 D3 receptors by risperidone and amisulpride. Psychopharmacol. 2005;180(4):664-669. (Pubitemid 41317862)
9. La Fougere C, Meisenzahl E, Schmitt G, et al. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: A 123 I-iodobenzamide SPECT study. J Nucl Med. 2005;46(6):1028-1033. (Pubitemid 43733520)
10. Perrault G, Schoemaker H, Scatton B. Amisulpride, an atypical neuroleptic. Encephale. 1996;22(spec. iss. 2):3-8.
11. Gessa G. Dysthymia and depressive disorders: Dopamine hypothesis. Eur Psychiatry. 1996;11(suppl 3):123s-127s. (Pubitemid 126658449)
12. Moller H-J. Amisulpride: Limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1101-1111.
13. Hamon-Vilcot B, Chaufour S, Deschamps C, et al. Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. Eur J Clini Pharmacol. 1998;54(5):405-409. (Pubitemid 28396313)
14. Puech A, Fleurot O, Rein W. misulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs haloperidol. Acta Psychiatr Scand. 1998;98(1):65-72. (Pubitemid 28289460)
15. Grunder G, Wetzel H, Schlosser R, et al. Neuroendocrine response to antipsychotics: Effects of drug type and gender. Biol Psychiatry. 1999;45(1):89-97. (Pubitemid 29049209)
16. Lambert M, Haro J, Novick D, et al. Olanzapine vs. other antipsychotics in actual out-patient settings: Six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand. 2005;111(3):232-243. (Pubitemid 40342192)
17. Caccia S. Biotransformation of post-clozapine antipsychotics. Pharmacological implications. Clini Pharmacokinet. 2000;38(5):393-414. (Pubitemid 30265260)
18. Moller H-J. Amisulpride: A review of its efficacy in schizophrenia. Acta Psychiatr Scand Suppl. 2000;101(400):17-22.
19. Laux G. Amisulpride for treatment in schizophrenia with positive symptoms. Psychopharmakotherapie. 2000;7(3):106-110. (Pubitemid 30643393)
20. Burns T, Bale R. Clinical advantages of amisulpride in the treatment of acute schizophrenia. J Int Med Res. 2001;29(6):451-466. (Pubitemid 34036825)
21. Coukell A, Spencer C, Benfield P. Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs. 1996;6(3):237-256. (Pubitemid 26306854)
22. Wetzel H, Grunder G, Hillert A, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - A double-blind controlled study comparing a selective D2-like antagonist to a mixed D1 D2-like antagonist. Psychopharmacol. 1998;137(3):223-232. (Pubitemid 28277507)
23. Freeman H. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studies. Int Clini Psychopharmacol. 1997;12(suppl 2):S11-S17. (Pubitemid 27286566)
24. Azorin J. Acute phase of schizophrenia: Impact of atypical antipsychotics. Int Clini Psychopharmacol. 2000;15(suppl 4):S5-S9. (Pubitemid 32171845)
25. Leucht S, Busch R, Hamann J, Kissling W, Kane J. Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended. Biol Psychiatry. 2005;57(12):1543-1549. (Pubitemid 40805384)
26. Bertolin Guillen J, Piles De La Fuente P, Vila Navarro C. Amisulpride in delusional disorders. An observational study. Arch Psiquiatria. 2005;68(4):301-308. (Pubitemid 43198785)
27. Scatton B, Claustre Y, Cudennec A, et al. Amisulpride: From animal pharmacology to therapeutic action. Int Clini Psychopharmacol. 1997;12(suppl 2):S29-S36. (Pubitemid 27286568)
28. Cudennec A, Fage D, Benavides J, et al. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat. Brain Res. 1997;768:257-265. (Pubitemid 27433499)
29. Danion J, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry. 1999;156:610-616. (Pubitemid 29162984)
30. Moller H, Van Praag H, Aufdembrinke B, et al. Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacol. 1994;115:221-228.
31. Loo H, Poirier-Littre M, Theron M, et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry. 1997;170:18-22. (Pubitemid 27404772)
32. Boyer P, Lecrubier Y, Peuch A, et al. Treatment negative symptoms in schizophrenia with amisulpride. Br J Psychiatry. 1995;166:68-72.
33. Rein W, Turjanski S. Clinical update on amisulpride in deficit schizophrenia. Int Clini Psychopharmacol. 1997;12(suppl 2):S19-S27. (Pubitemid 27286567)
34. Moller H, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol. Psychopharmacol. 1997;132(4):396-401. (Pubitemid 27373482)
35. Peuskens J, Bech P, Moller H-J, Bale R, Fleurot O, Rein W. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res. 1999;88(2):107-117. (Pubitemid 29507525)
36. Speller J, Barnes T, Curson D, Pantelis C, Alberts J. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry. 1997;171:564-568. (Pubitemid 27527328)
37. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clini Psychopharmacol. 2000;15(1):13-22. (Pubitemid 30058134)
38. Leucht S. Amisulpride - A selective dopamine antagonist and atypical antipsychotic: Results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2004;7(suppl 1):S15-S20. (Pubitemid 38436992)
39. Vaiva G, Thomas P, Llorca P, et al. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res. 2002;115(1-2):37-48. (Pubitemid 34880097)
40. Storosum J, Elferink A, Van Zwieten B, Van Strik R, Hoogendijk W, Broekmans A. Amisulpride: Is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull. 2002;28(2):193-201. (Pubitemid 35462237)
41. Olie J-P, Spina E, Murray S, Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: Results of a 12-week, double-blind study. Int Clini Psychopharmacol. 2006;21(3):143-151. (Pubitemid 43740305)
42. Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: Olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatrica Scand. 2006;114(5):319-327. (Pubitemid 44521299)
43. Chiaie R, Caliari P. Chronic mild depressive symptoms: Rational use of amisulpride. Rivista di Psichiatria. 1997;32(suppl 6):77-93. (Pubitemid 28332197)
44. Pani L, Gessa G. The role of dopamine in the biological basis of dysthymia. Ital J Psychiatr Behav Sci. 1998;8(1):5-9. (Pubitemid 29009441)
45. Papp M, Wieronska J. Antidepressant-like activity of amisulpride in two animal models of depression. J Psychopharmacol. 2000;14(1):46-52. (Pubitemid 30156538)
46. Boyer P, Lecrubier Y. Atypical antipsychotic drugs in dysthymia: Placebo controlled studies of amisulpride versus imipramine, versus amineptine. Eur Psychiatry. 1996;11(suppl 3):135s-140s. (Pubitemid 126658451)
47. Smeraldi E, Haefele E, Crespi G, Casadei G, Biondi F, Vigorelli E. Amisulpride versus fluoxetine in dysthymia: Preliminary results of a double-blind comparative study. Eur Psychiatry. 1996;11(suppl 3):141s-143s. (Pubitemid 126658452)
48. Paes De Sousa M. Amisulpride in dysthymia: Results of a naturalistic study in general practice. Eur Psychiatry. 1996;11(suppl 3):145s-147s. (Pubitemid 126658453)
49. Bogetto F, Barzega G, Bellino S, Maina G, Ravizza L. Drug treatment of dysthymia: A clinical study. Rivista di Psichiatria. 1997;32(1):1-5. (Pubitemid 27228966)
50. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiol. 1999;39(1):25-32. (Pubitemid 29037761)
51. Ravizza L. Amisulpride in medium-term treatment of dysthymia: A six-month, double-blind safety study versus amitriptyline. J Psychopharmacol. 1999;13(3):248-254. (Pubitemid 29435785)
52. Rocca P, Fonzo V, Ravizza L, et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord. 2002;70(3):313-317. (Pubitemid 34786647)
53. Montgomery S. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clini Psychopharmacol. 2002;17(suppl 4):S9-S19. (Pubitemid 36127066)
54. Ceskova E. Deniban in the treatment of dysthymia. Ceska Slove Psychiatr. 2007;103(2):73-79.
55. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol. 2006;16(4):281-287.
56. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amilsulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord. 1997;43(2):95-103. (Pubitemid 27221927)
57. Amore M, Jori M. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: A randomized, double-blind, parallel group study. Int Clini Psychopharmacol. 2001;16(6):317-324. (Pubitemid 33030046)
58. Cassano G, Jori M. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: A randomized, double-blind, parallel group study. Int Clini Psychopharmacol. 2002;17(1):27-32. (Pubitemid 34056522)
59. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study. J Affect Disord. 1998;48(1):47-56. (Pubitemid 28078970)
60. Canal M, Legangneux E, Van Lier J, Van Viet A, Coulouvrat C. Lack of effect of amisulpride on the pharmacokinetics and safety of lithium. Int J Neuropsychopharmacol. 2003;6(2):103-109. (Pubitemid 36850961)
61. Svestka J. New psychotropics: Amisulpride - Atypical compound in the group of 2nd generation antipsychotics. Psychiatrie. 2000;4(3):191-200. (Pubitemid 30944115)
62. Peuskens J, Moller H, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol. 2002;12(4):05-310. (Pubitemid 34753101)
63. Vanelle J-M, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry. 2006;21(8):523-530.
64. Kim S-W, Shin L-S, Kim J-M, et al. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial. Progr in Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1504-1509. (Pubitemid 47307407)
65. Hafner H, Maurer K, Ruhmann S, et al. Early detection and secondary prevention of psychosis: Facts and visions. Eur Archi Psychiatry Clini Neurosci. 2004;254(2):117-128. (Pubitemid 39304479)
66. Bechdolf A, Ruhmann S, Wagner M, et al. Interventions in the initial prodromal states of psychosis in Germany: Concept and recruitment. Br J Psychiatry. 2005;187(suppl 48):s45-s48. (Pubitemid 41139665)
67. Ruhmann S, Bechdolf A, Kuhn K, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry. 2007;191(suppl 51):s88-s95. (Pubitemid 350273195)
68. Murphy B, Stuart A, Wade D, Cotton S, McGorry P. Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: A pilot study. Hum Psychopharmacol. 2006;21(8):511-517. (Pubitemid 46062139)
69. Kahn R, Fleischhacker W, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(96110858):1097.
70. Kontaxakis V, Havaki-Kontaxaki B, Ferentinos P, Paplos K, Soldatos C. Switching to amisulpride monotherapy for treatment-resistant schizophrenia. Eur Psychiatry. 2006;21(3):214-217.
71. Croissant B, Hermann D, Olbrich R. Saving potential of clozapine due to combination with amisulpride. Psychopharmakotherapie. 2001;8(3):128-130. (Pubitemid 32851535)
72. Kampf P, Agelink M, Mass R, John H, Schafer I, Naber D. Amisulpride in addition to clozapine: A retrospective study indicates improved efficacy and good tolerability. Ger J Psychiatry. 2003;6(3):64-68. (Pubitemid 38097555)
73. Zink M, Knopf U, Henn F, Thome J. Combination of Clozapine and Amisulpride in Treatment-Resistant Schizophrenia - Case Reports and Review of the Literature. Pharmacopsychiatry. 2004b;37(1):26-31. (Pubitemid 38230736)
74. Cook B, Hoogenboom G. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia. Australas Psychiatry. 2004;12(1):74-76. (Pubitemid 38488964)
75. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: An open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand. 2004;110(4):292-298. (Pubitemid 39278988)
76. Frick A, Kopitz J, Kress K, Bergemann N. Clozapine raises plasma levels of amisulpride. Psychopharmakotherapie. 2003;10(1):28-31. (Pubitemid 36249498)
77. Zink M, Henn F, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry. 2004a;19(1):56-58. (Pubitemid 38210430)
78. Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: A review of current evidence. J Psychopharmacol. 2007;21(6):657-664. (Pubitemid 47472722)
79. Lerner V, Bergman J, Borokhov A, Loewenthal U, Miodownik C. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clini Neuropharmacol. 2005;28(2):66-71. (Pubitemid 40471879)
80. Zink M, Dressing H. Augmenting atypical antipsychotic medications with clozapin. Nervenarzt. 2005;76(9):1092-1102. (Pubitemid 41296854)
81. Ziegenbein M, Sieberer M, Kuenzel H, Kropp S. Augmentation of Clozapine with amisulpride in patients with treatment-resistant schizophrenia an open clinical study. Ger J Psychiatry. 2006;9(1):17-22. (Pubitemid 43141534)
82. Koen L, Niehaus D, Schulte A, Muller J, Emsley R, Oosthulzen P. Amisulpride as adjunct to clozapine in treatment-resistant schizophrenia and schizoaffective disorder: An open-label pilot study. Afr J Psychiatry (Johannesbg). 2006;12(1):17-20.
83. Assion H-J, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2008;41(1):24-28. (Pubitemid 351195889)
84. Genc Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study. Adv Ther. 2007;24(1):1-13. (Pubitemid 46700860)
85. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: A randomized, double-blind, placebo-controlled cross-over study. Int Clini Psychopharmacol. 2006;21(2):99-103. (Pubitemid 43740317)
86. Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: A review of treatment strategies. Can J Psychiatry. 2007;52(6):377-384. (Pubitemid 46997312)
87. Mattila M, Patat A, Seppala T, et al. Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. Eur J Clin Pharmacol. 1996;51(2):161-166. (Pubitemid 26342773)
88. Patat A, Rosenzweig P, Miget N, Allain H, Gandon J-M. Effects of 50 mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects. Fund Clini Pharmacol. 1999;13(5):582-594. (Pubitemid 30706569)
89. Peretti C, Danion J, Kauffmann-Muller F, Grange D, Patat A, Rosenzweig P. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Psychopharmacol. 1997;131(4):329-338. (Pubitemid 27348698)
90. Perault M, Bergougnan L, Paillat A, Zieleniuk I, Rosenzweig P, Vandel B. Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers. Hum Psychopharmacol. 1998;13(7):493-500. (Pubitemid 28479501)
91. Ramaekers J, Louwerens J, Muntjewerff N, et al. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clini Psychopharmacol. 1999;19(3):209-221. (Pubitemid 29233015)
92. Legangneux E, McEwen J, Wesnes K, et al. The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J Psychopharmacol. 2000;14(2):164-171. (Pubitemid 30389490)
93. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002;17(1):1-13. (Pubitemid 34130349)
94. Gibbs A, Naudts K, Spencer E, David A. The role of dopamine in attentional and memory biases for emotional information. Am J Psychiatry. 2007;164(10):1601-6093. (Pubitemid 350069741)
95. Morrens M, Hulstijn W, Sabbe B. The effects of atypical and conventional antipsychotics on reduced processing speed and psychomotor slowing in schizophrenia: A cross-sectional exploratory study. Clini Ther. 2008;30(4):684-692. (Pubitemid 351680498)
96. Wang Y-T, Chiu N-Y, Jou S-H, et al. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. Int J Psychiatry Clini Pract. 2008;12(3):180-186.
97. Tyson P, Roberts K, Mortimer A. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004;114(6);593-611. (Pubitemid 38679903)
98. Wagner M, Quednow B, Westeide J, Schlaepfer T, Maier W, Kuhn K-U. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: Randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacol. 2005;30(2):381-390. (Pubitemid 40129489)
99. Mortimer A, Joyce E, Balasubramaniam D, Choudhary P, Saleem P. Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. Hum Psychopharmacol. 2007;22(7):445-454. (Pubitemid 47611299)
100. Chabannes J, Pelissolo A, Farah S, Gerrard D. Treatment of psychosis with productive symptoms: Efficacy and safety of amisulpride. Encephale. 1998;24(4):386-392. (Pubitemid 28462397)
101. Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: Results of a multicentre, double-blind study (the amisulpride study group). Eur Psychiatry. 2000;15(5):321-329. (Pubitemid 30643936)
102. Saleem P, Olie J, Loo H. Social functioning and quality of life in the schizophrenic patient: Advantages of amisulpride. Int Clini Psychopharmacol. 2002;17(1):1-8. (Pubitemid 34056519)
103. Surguladze S, Patel A, Kerwin R, Knapp M, Travis M. Cost analysis of treating schizophrenia with amisulpride: Naturalistic mirror image study. Prog in Neuropsychopharmacol Biol Psychiatry. 2005;29(4):517-522. (Pubitemid 40603825)
104. Tyson P, Laws K, Flowers K, Tyson A, Mortimer A. Cognitive function and social abilities in patients with schizophrenia: Relationship with atypical antipsychotics. Psychiatry Clini Neurosci. 2006;60(4):473-479. (Pubitemid 44060805)
105. Lambert M, Naber D, Eich F, Schacht M, Linden M, Schimmelmann B. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatri Scand. 2007;1110625(113). (Pubitemid 46114871)
106. Falkai P, Vogeley K. Chances of new atypical substances. Fortschr Neurol Psychiatr. 2000;68(suppl 1):S32-S37.
107. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371-1376.
108. Barnett D. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. National Institute for Clinical Excellence. London. 2002;43.
109. Hugenholtz G, Heerdink E, Stolker J, Meijer W, Egberts A, Nolen W. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: Comparison with officially recommended doses. Source J Clin Psychiatry. 2006;67(6):897-903. (Pubitemid 44049088)
110. Ceskova E. Amisulpride - A new benzamide antipsychotic of the second generation. Ceska a Slovenska Psychiatrie. 2000;96(8):411-415. (Pubitemid 32095479)
111. Peuskens J. Switching approach in the management of schizophrenia patients. Int Clini Psychopharmacol. 2000;15(suppl 4):S15-S19. (Pubitemid 32171847)
112. Pani L, Villagran J, Kontaxakis V, Alptekin K. Practical issues with amisulpride in the management of patients with schizophrenia. Clini Drug Investig. 2008;28(8):465-477. (Pubitemid 351948049)
113. Burns T, Chabannes J, Demyttenaere K. Switching antipsychotic medications: General recommendations and switching to amisulpride. Curr Med Res Opin. 2002;18(4):201-208. (Pubitemid 34886823)
114. Haro J, Novick D, Belger M, Jones P. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry. 2006;21(1):41-47. (Pubitemid 43243051)
115. Kahn R, Fleischhaker W, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.
116. Linden M, Scheel T, Eich F-X. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. J Psychopharmacol. 2006;20(6):815-823. (Pubitemid 44622746)
117. Nuss P, Hummer M, Tessier C. The use of amisulpride in the treatment of acute psychosis. Ther Clini Risk Manage. 2007;3(1):3-11. (Pubitemid 46671818)
118. Lecrubier Y. Is amisulpride an 'atypical' atypical antipsychotic agent? Int Clin Psychopharmacol. 2000;15(suppl 4):S21-S26.
119. Curran M, Perry C. Amisulpride: A review of its use in the management of schizophrenia. Drugs. 2001;61(14):2123-2150. (Pubitemid 33135193)
120. Leucht S, Pitschel-Walz G, Engel R, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: A meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159(2):180-190.
121. Davis J, Chen N, Glick I. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6): 553-564.
122. Leucht S, Corves C, Arbter D, Engel R, Li C, Davis J. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
123. Naber D, Arlt J, Lambert M. Amisulpride: A safe and effective option for the long-term treatment of patients with schizophrenia. Int J Psychiatry Clini Pract. 2003;7(3):167-175. (Pubitemid 37205363)
124. Herrera-Estrella M, Apiquian R, Fresan A, Sanchez-Torres I.Institution. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: A prospective open-label study. BMC Psychiatry. 2005;5(22). (Pubitemid 41460704)
125. McKeage K, Plosker G. Amisulpride: A review of its use in the management of schizophrenia. CNS Drugs. 2004;18(13):933-956. (Pubitemid 39612020)
126. Rein W, Coulouvrat C, Dondey-Nouvel L. Safety profile of amisulpride in short- and long-term use. Acta Psychiatr Scand. 2000;Suppl 101(400):23-27. (Pubitemid 30225751)
127. Curran M, Perry C. Spotlight on amisulpride in schizophrenia. CNS Drugs. 2002;16(3):207-211.
128. Linden M, Scheel T, Eich F. Dosage finding and outcome in the treatment of schizophrenic inpatients with amilsupride. Results of a drug utilization observation study. Hum Psychopharmacol. 2004;19(2):111-119. (Pubitemid 38332058)
129. Muller M, Wetzel H, Eich F-X, Rein W, Puech A, Benkert O. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. J Clini Psychopharmacol. 2002;22(6):554-560. (Pubitemid 35416780)
130. Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs. risperidone in chronic schizophrenia: Results of a 6-month double-blind study. Neuropsychopharmacol. 2002;27(6):1071-1081. (Pubitemid 35447644)
131. Hwang T, Lee S-M, Sun H-J, et al. Amisulpride versus risperidone in the treatment of schizophrenic patients: A double-blind pilot study in Taiwan. J Form Med Assoc. 2003;102(1):30-36. (Pubitemid 36656417)
132. Mortimer A. How do we choose between atypical antipsychotics? The advantages of amisulpride. Int J Neuropsychopharmacol. 2004;7(suppl 1):S21-S25. (Pubitemid 38436993)
133. Hofer A, Rettenbacher M, Edlinger M, et al. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. Pharmacopsychiatry. 2007;40(1):1-8. (Pubitemid 46568353)
134. Motlova L, Spaniel F, Hoschl C, Balon R. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders? Ann Clini Psychiatry. 2007;19(2):133-143. (Pubitemid 47035941)
135. Vohora D. Atypical antipsychotic drugs: Current issues of safety and efficacy in the management of schizophrenia. Curr Opin Investig Drugs. 2007;8(7):531-538. (Pubitemid 47016321)
136. Mortimer A, Martin S, Loo H, Peuskens J. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clini Psychopharmacol. 2004;19(2):63-69. (Pubitemid 38316764)
137. Manschreck T, Boshes R. The CATIE Schizophrenia Trial: results, impact, controversy. Mol Psychiatry. 2007;245-258. (Pubitemid 47557208)
138. Lewis S, Lieberman J. CATIE and CUtLASS: Can we handle the truth? Br J Psychiatry. 2008;192(3):161-163. (Pubitemid 351347371)
139. Lewis S, Davies L, Jones P, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess. 2006;10(17):1-94. (Pubitemid 43940726)